CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients
The webinar panelists include:
- Robert A. Watson III, MD, FAAC, Chief, Cardiology Division, Co-Director, Comprehensive Heart Failure Program at
Abington Jefferson Health, Pennsylvania Donald C. Haas, MD, Medical Director, Ventricular Assist Device Program; Co-Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania Maureen Hummel, CRNP, Clinical Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania Patti Barrella, MSN, CHFN, Heart Failure Coordinator at Abington Jefferson Health, Pennsylvania John L. Jefferies, Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center
90% of the nearly 1 million annual heart failure hospitalizations in the
Those interested in attending the educational webinar can register through this link. For those unable to attend the webinar, an archive of the webcast will be available within 48 hours after the event concludes on the CHF Solutions’ YouTube channel. and CHF Solutions’ website.
1. Costanzo MR, et al. J Am Coll Cardiol. 2007 Feb 13; 49(6): 675-683.
2. Gheorghiade M, Filippatos G. Eur Heart J. 2005 Mar 15; 7 (Suppl): B13-B19.
3. Miller WL. Circ Heart Fail.206;9:e002922-31
About the Aquadex System
The Aquadex SmartFlow™ system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the use of Aquadex technology to treat heart failure patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Chief Financial Officer,
firstname.lastname@example.org Matt.email@example.com firstname.lastname@example.org
Source: CHF Solutions, Inc.